2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by PRICE, D. A. Articles by HOLLENBERG, N. K. Search for Related Content PubMed PubMed Citation Articles by PRICE, D. A. Articles by HOLLENBERG, N. K.

The Paradox of the Low-Renin State in Diabetic Nephropathy

Departments of Medicine and Radiology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.

Correspondence to Dr. Deborah A. Price, c/o Norman K. Hollenberg, Brigham and Women's Hospital, 15 Francis Street, Boston, MA 02115. Phone: 617-732-5834; Fax: 617-232-2869; E-mail: daprice{at}bics.bwh.harvard.edu

Abstract. Although diabetic nephropathy is often a low renin state, the renin system appears to be implicated in its pathogenesis. In this study, it was hypothesized that the low plasma renin activity (PRA) is misleading, masking and perhaps reflecting an activated intrarenal renin system. PRA and renal vascular responses (inulin and para-aminohippurate clearance) to graded doses of an angiotensin II (AngII) antagonist, irbesartan, were assessed in eight healthy volunteers and 12 patients with type 2 diabetes mellitus and nephropathy on a 10 mmol Na intake, to activate the renin system. Basal PRA was suppressed in type 2 diabetes mellitus compared with the healthy subjects (0.58 ± 0.14 versus 1.58 ± 0.28 ng/L per s, mean ± SEM; P < 0.01). Despite the low PRA, renal perfusion rose more in response to irbesartan in type 2 diabetes mellitus (714 ± 83 to 931 ± 116 ml/min; P = 0.002) than normal (624 ± 29 to 772 ± 49 ml/min; P = 0.008). The youngest patients were hyperfiltrating and showed the largest rise in renal plasma flow in response to irbesartan, whereas renal plasma flow rose less and GFR fell in patients with low basal GFR. PRA rose in response to irbesartan more gradually in the patients with type 2 diabetes mellitus, but ultimately matched the normal response. To account for the apparent paradox of a heightened renal hemodynamic response to an AngII antagonist in the face of a low PRA in type 2 diabetes mellitus, and the rise in PRA following the AngII antagonist, it is proposed that there is increased intrarenal AngII production in type 2 diabetes mellitus. This increase could account for suppressed circulating renin, the exaggerated renal vasodilator response to irbesartan, and the therapeutic effectiveness of interrupting the renin system in diabetic nephropathy.

This article has been cited by other articles:

				Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, and Y. C. Li Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase PNAS, October 14, 2008; 105(41): 15896 - 15901. [Abstract] [Full Text] [PDF]

				J. Zhang, N. A. Noble, W. A. Border, R. T. Owens, and Y. Huang Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E810 - E819. [Abstract] [Full Text] [PDF]

				B. Hohenstein Reply Nephrol. Dial. Transplant., September 1, 2008; 23(9): 3037 - 3038. [Full Text] [PDF]

				P. C. Cristovam, C. P. Arnoni, M. C. C. de Andrade, D. E. Casarini, L. G. Pereira, N. Schor, and M. A. Boim ACE-Dependent and Chymase-Dependent Angiotensin II Generation in Normal and Glucose-Stimulated Human Mesangial Cells Experimental Biology and Medicine, August 1, 2008; 233(8): 1035 - 1043. [Abstract] [Full Text] [PDF]

				M. W. Brands and H. Labazi Role of Glomerular Filtration Rate in Controlling Blood Pressure Early in Diabetes Hypertension, August 1, 2008; 52(2): 188 - 194. [Full Text] [PDF]

				N. D.L. Fisher, A.H. Jan Danser, J. Nussberger, W. P. Dole, and N. K. Hollenberg Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans Circulation, June 24, 2008; 117(25): 3199 - 3205. [Abstract] [Full Text] [PDF]

				J. J. Kang, I. Toma, A. Sipos, E. J. Meer, S. L. Vargas, and J. Peti-Peterdi The Collecting Duct Is the Major Source of Prorenin in Diabetes Hypertension, June 1, 2008; 51(6): 1597 - 1604. [Abstract] [Full Text] [PDF]

				R. V. Durvasula and S. J. Shankland Activation of a local renin angiotensin system in podocytes by glucose Am J Physiol Renal Physiol, April 1, 2008; 294(4): F830 - F839. [Abstract] [Full Text] [PDF]

				A. H. Gradman and R. Kad Renin inhibition in hypertension. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 519 - 528. [Abstract] [Full Text] [PDF]

				H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]

				R. D Stevanovic, N. D. Fisher, C. M Lansang, K. D Freeman, and N. K Hollenberg Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 85 - 92. [Abstract] [PDF]

				A. R. Stankovic, N. D.L. Fisher, and N. K. Hollenberg Prorenin and Angiotensin-Dependent Renal Vasoconstriction in Type 1 and Type 2 Diabetes J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3293 - 3299. [Abstract] [Full Text] [PDF]

				J. R. Ingelfinger ACE2: A New Target for Prevention of Diabetic Nephropathy? J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2957 - 2959. [Full Text] [PDF]

				A.-M. Samuelsson, C. Alexanderson, J. Molne, B. Haraldsson, P. Hansell, and A. Holmang Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat J. Physiol., September 15, 2006; 575(3): 855 - 867. [Abstract] [Full Text] [PDF]

				M C. Lansang, C. Coletti, S. Ahmed, M. S Gordon, and N. K Hollenberg Effects of the PPAR-{gamma} Agonist Rosiglitazone on Renal Haemodynamics and the Renin-Angiotensin System in Diabetes Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 175 - 180. [Abstract] [PDF]

				S. Itoh, B. Ding, T. Shishido, N. Lerner-Marmarosh, N. Wang, N. Maekawa, B. C. Berk, Y. Takeishi, C. Yan, B. C. Blaxall, et al. Role of p90 Ribosomal S6 Kinase-Mediated Prorenin-Converting Enzyme in Ischemic and Diabetic Myocardium Circulation, April 11, 2006; 113(14): 1787 - 1798. [Abstract] [Full Text] [PDF]

				S. B. Ahmed, N. D.L. Fisher, R. Stevanovic, and N. K. Hollenberg Body Mass Index and Angiotensin-Dependent Control of the Renal Circulation in Healthy Humans Hypertension, December 1, 2005; 46(6): 1316 - 1320. [Abstract] [Full Text] [PDF]

				S. B. Ahmed, P. Hovind, H.-H. Parving, P. Rossing, D. A. Price, L. M. Laffel, M. C. Lansang, R. Stevanovic, N. D.L. Fisher, and N. K. Hollenberg Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy Diabetes Care, August 1, 2005; 28(8): 1988 - 1994. [Abstract] [Full Text] [PDF]

				P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]

				R. D Stevanovic, D. A Price, M C. Lansang, N. D. Fisher, L. M. Laffel, and N. K Hollenberg Renin Release in Response to Renin System Blockade: Activation of the Renin System in Type 1 Diabetes Mellitus Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 78 - 83. [Abstract] [PDF]

				P. K. Jacobsen Preventing end stage renal disease in diabetic patients -- genetic aspect (part I) Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 1 - 14. [Abstract] [PDF]

				D. Feliers, S. Duraisamy, J. L. Barnes, G. Ghosh-Choudhury, and B. S. Kasinath Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II Am J Physiol Renal Physiol, March 1, 2005; 288(3): F521 - F529. [Abstract] [Full Text] [PDF]

				A. M. Sharma Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension? Hypertension, July 1, 2004; 44(1): 12 - 19. [Abstract] [Full Text] [PDF]

				D. B. Vidotti, D. E. Casarini, P. C. Cristovam, C. A. Leite, N. Schor, and M. A. Boim High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1039 - F1045. [Abstract] [Full Text] [PDF]

				S. Arima and S. Ito The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1966 - 1969. [Full Text] [PDF]

				S. Sonkodi and A. Mogyorosi Treatment of diabetic nephropathy with angiotensin II blockers Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v21 - 23. [Abstract] [Full Text] [PDF]

				R. Singh, A. K. Singh, N. Alavi, and D. J. Leehey Mechanism of Increased Angiotensin II Levels in Glomerular Mesangial Cells Cultured in High Glucose J. Am. Soc. Nephrol., April 1, 2003; 14(4): 873 - 880. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff and J. C. Romero Role of oxidative stress in angiotensin-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R893 - R912. [Abstract] [Full Text] [PDF]

				H. Taniwaki, E. Ishimura, T. Kawagishi, N. Matsumoto, M. Hosoi, M. Emoto, T. Shoji, S. Shoji, T. Nakatani, M. Inaba, et al. Intrarenal Hemodynamic Changes After Captopril Test in Patients With Type 2 Diabetes: A duplex Doppler sonography study Diabetes Care, January 1, 2003; 26(1): 132 - 137. [Abstract] [Full Text] [PDF]

				D. A. Price, N. D.L. Fisher, M. C. Lansang, R. Stevanovic, G. H. Williams, and N. K. Hollenberg Renal Perfusion in Blacks: Alterations Caused by Insuppressibility of Intrarenal Renin With Salt Hypertension, August 1, 2002; 40(2): 186 - 189. [Abstract] [Full Text] [PDF]

				M. C. Lansang and N. K. Hollenberg Renal Perfusion and the Renal Hemodynamic Response to Blocking the Renin System in Diabetes: Are the Forces Leading to Vasodilation and Vasoconstriction Linked? Diabetes, July 1, 2002; 51(7): 2025 - 2028. [Abstract] [Full Text] [PDF]

				M C. Lansang, S. Y Osei, C. Coletti, J. Krupinski, and N. K Hollenberg Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 19 - 23. [Abstract] [PDF]

				E. J. Lewis, L. G. Hunsicker, W. R. Clarke, T. Berl, M. A. Pohl, J. B. Lewis, E. Ritz, R. C. Atkins, R. Rohde, I. Raz, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes N. Engl. J. Med., September 20, 2001; 345(12): 851 - 860. [Abstract] [Full Text] [PDF]

				R. Toto Angiotensin II Subtype 1 Receptor Blockers and Renal Function Arch Intern Med, June 25, 2001; 161(12): 1492 - 1499. [Abstract] [Full Text] [PDF]

				N. K Hollenberg Review: The renin-angiotensin-aldosterone system, blockade and diabetic nephropathy Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S185 - S187. [PDF]

				M. C. Lansang, S. Y. Osei, D. A. Price, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic and Hormonal Responses to the Angiotensin II Antagonist Candesartan Hypertension, November 1, 2000; 36(5): 834 - 838. [Abstract] [Full Text] [PDF]

				M. S Gordon, D. A Price, and N. K Hollenberg Blunted suppression of plasma renin activity in diabetes Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 252 - 256. [Abstract] [PDF]

				S. Y. Osei, D. A. Price, L. M. B. Laffel, M. C. Lansang, and N. K. Hollenberg Effect of Angiotensin II Antagonist Eprosartan on Hyperglycemia-Induced Activation of Intrarenal Renin-Angiotensin System in Healthy Humans Hypertension, July 1, 2000; 36(1): 122 - 126. [Abstract] [Full Text] [PDF]

				N. K. Hollenberg Implications of Species Difference for Clinical Investigation : Studies on the Renin-Angiotensin System Hypertension, January 1, 2000; 35(1): 150 - 154. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673